Cargando…
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
OBJECTIVE: Longer time to progression (TTP) is associated with prolonged post-progression survival (PPS) in anaplastic lymphoma kinase+non-small cell lung cancer (NSCLC). This study evaluated whether TTP is associated with PPS among previously treated patients with metastatic v-Raf murine sarcoma vi...
Autores principales: | Li, Junlong, Sasane, Medha, Zhang, Jie, Zhao, Jing, Ricculli, Marie Louise, Yao, Zhiwen, Redhu, Suman, Signorovitch, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104743/ https://www.ncbi.nlm.nih.gov/pubmed/30121602 http://dx.doi.org/10.1136/bmjopen-2018-021642 |
Ejemplares similares
-
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018) -
DRP1 Promotes BRAF(V600E)-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer
por: Padder, Rayees Ahmad, et al.
Publicado: (2021) -
Mucinous borderline ovarian tumors with BRAF(V600E) mutation may have low risk for progression to invasive carcinomas
por: Ohnishi, Kaori, et al.
Publicado: (2020) -
Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis
por: Hong, Ling, et al.
Publicado: (2022) -
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
por: Fusco, Michael J., et al.
Publicado: (2021)